Risk factors, genetic mutations and prevention of breast cancer

Paper Details

Review Paper 01/04/2019
Views (404) Download (17)
current_issue_feature_image
publication_file

Risk factors, genetic mutations and prevention of breast cancer

Muhammad Naeem, Muhammad Hayat, Sarmad Ahmad Qamar, Tariq Mehmood, Ahmad Munir, Ghafoor Ahmad, Umair Rasool Azmi, Muhammad Adeel Faryad, Muhammad Zeeshan Talib, Muhammad Irfan, Asim Hussain, Muhammad Awais Hayder, Usman Ghani, Faisal Mehmood
Int. J. Biosci.14( 4), 480-484, April 2019.
Certificate: IJB 2019 [Generate Certificate]

Abstract

Breast cancer is the second leading cause of cancer deaths among women. The breast is generally common site of noncutaneous cancer among women. Numerous genetic and clinical factors are involved in increasing the risk of developing breast cancer among women. This review focused on pathogenesis, related genes, risk factors and preventive methods that implement on the breast cancer over past years strategies in present use to stop breast cancer, as well as prospective approach that could be used in future. A set of somatic alterations as well as mutations and also gene amplifications are involved in etiology of various forms of breast cancer. Diagnosis of breast cancer at the Initial stages is one of the most excellent approaches to prevent this disease. Presently, people have supplementary drug option for the chemoprevention of breast cancer, while prevention using biological methods has been in recent times developed to recover quality of life of patients suffering from breast cancer. In addition, prevention clinical trials are starting to estimate multi agent cancer prevention approach with the expectation of improved effectiveness over single agents.

VIEWS 21

Bethea TN, Rusenburg L, Hong CC. 2015. A case control analysis of oral contraceptive use and breast cancer subtypes in the African, Amarican Breast Cancer Epediomology And Risk Consortium. Breast Cancer Research 17, 2296.

Bogdanova N, Fishchenko S, lazjuk GI, Rogov YI, Dammann O, Dork T. 2005. Association of two mutaions in the CHECK2 gene with breast cancer. International journal of cancer 116(2), 263-266.

Bozovic I, Azambuj E. 2012. Chemoprevension for breast cancer. Cancer treatment Review (38), 329-339.

Cho HS, Mason K, Ramyar KX. 2013. Structure of the extracellular region of HER2 alone and in complex with herecptin. Fab. Nature (421), 756-760.

Dall Gv, Britt KL. 2017. Estrogen Effects of the Mammary gland in Early and Late Life and breast cancer Risk. Frontier Oncology 7, 110.

Ford D, Eston D, Stratton M, Narod S. 1998. Genetic Hetrogeneity and penetrance analysis of the BRACA1 and BRAC2 genes in the breast cancer families. The Amarican Journal of Human Genetics 62(3), 676-689.

Hamdi Y, Soucy P, Odoue V, Michailidou K, Canisius S, Lemacore. 2016. Association of breast cancer risk with genetic variants showing differential allelic expression, Identification of novel breast cancer susciptability locus at 4q21. Oncotarget 7(49), 80140.

Jiao X, Aravidis C, Marikkanno R, Rantala J,Picelli S Adamovic T. 2017. PHIP-a novel candidate breast cancer susciptiblity Locus on 6q14.1.1, Oncotarget (8)61, 102769.

Klili J, Afif M, Elcacemi H, Benoulaid M, Kebdani T. 2015. Breast cancer associated with neurofibromatosis type 1, A case series and review of literature. Journal of medical case reports (9), 61.

Majima N, Hirose K, Tajima K. 2002. Alcohol, tobacco and breast cancer collaborative reanalysis of individual data from 53Epidiomological studies, including 58,515 women with breast cancer and 95,067 Women without disease. Brithis Journal of Cancer (87), 1234-1245.

Mataoba S, Kang JG, Patino WD, Wragge A, Boehm M. 2006. P53 regulates mitochondrial respiration. Science 312(5780), 1650-1653.

Paluch S, Cardosa, F, Sessa C. 2016. Prevention and screening of BRCA mutations carriers and other breast and ovarien hereditary cancer syndrome. ESMO clinical practice giudline for cancer prevention and screening. Annal oncology (27), 103-110.

Rizzalo P, Silvestri V, Fallchitti M. 2011. Inherited and acquired alterations in development of cancer. The application of clinical genetics (4), 145-158.

Siegel RL, Miller KD, Jamil A. 2017. Cancer statistics, CA Cancer Journal for Clinicians (67), 7-30.

Valastyan S, weinburg RA. 2011. Tumour meta stasis: Molecular insights and evolving paradigms cell (147), 275-292.